Literature DB >> 30005866

Global Transcriptional Response to CRISPR/Cas9-AAV6-Based Genome Editing in CD34+ Hematopoietic Stem and Progenitor Cells.

M Kyle Cromer1, Sriram Vaidyanathan1, Daniel E Ryan2, Bo Curry2, Anne Bergstrom Lucas2, Joab Camarena1, Milan Kaushik1, Sarah R Hay1, Renata M Martin1, Israel Steinfeld2, Rasmus O Bak1, Daniel P Dever1, Ayal Hendel3, Laurakay Bruhn2, Matthew H Porteus4.   

Abstract

Genome-editing technologies are currently being translated to the clinic. However, cellular effects of the editing machinery have yet to be fully elucidated. Here, we performed global microarray-based gene expression measurements on human CD34+ hematopoietic stem and progenitor cells that underwent editing. We probed effects of the entire editing process as well as each component individually, including electroporation, Cas9 (mRNA or protein) with chemically modified sgRNA, and AAV6 transduction. We identified differentially expressed genes relative to control treatments, which displayed enrichment for particular biological processes. All editing machinery components elicited immune, stress, and apoptotic responses. Cas9 mRNA invoked the greatest amount of transcriptional change, eliciting a distinct viral response and global transcriptional downregulation, particularly of metabolic and cell cycle processes. Electroporation also induced significant transcriptional change, with notable downregulation of metabolic processes. Surprisingly, AAV6 evoked no detectable viral response. We also found Cas9/sgRNA ribonucleoprotein treatment to be well tolerated, in spite of eliciting a DNA damage signature. Overall, this data establishes a benchmark for cellular tolerance of CRISPR/Cas9-AAV6-based genome editing, ensuring that the clinical protocol is as safe and efficient as possible.
Copyright © 2018 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  RNA expression analysis; genome editing; hematopoietic stem cells

Mesh:

Substances:

Year:  2018        PMID: 30005866      PMCID: PMC6171165          DOI: 10.1016/j.ymthe.2018.06.002

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  55 in total

1.  Efficient gene targeting mediated by adeno-associated virus and DNA double-strand breaks.

Authors:  Matthew H Porteus; Toni Cathomen; Matthew D Weitzman; David Baltimore
Journal:  Mol Cell Biol       Date:  2003-05       Impact factor: 4.272

Review 2.  Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease.

Authors:  Megan D Hoban; Stuart H Orkin; Daniel E Bauer
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

3.  A new pathway of translational regulation mediated by eukaryotic initiation factor 3.

Authors:  J Guo; D J Hui; W C Merrick; G C Sen
Journal:  EMBO J       Date:  2000-12-15       Impact factor: 11.598

4.  Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors.

Authors:  Anne-Kathrin Zaiss; Qiang Liu; Gloria P Bowen; Norman C W Wong; Jeffrey S Bartlett; Daniel A Muruve
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 5.  Regulation of type I interferon responses.

Authors:  Lionel B Ivashkiv; Laura T Donlin
Journal:  Nat Rev Immunol       Date:  2014-01       Impact factor: 53.106

6.  Role of the Akt pathway in mRNA translation of interferon-stimulated genes.

Authors:  Surinder Kaur; Antonella Sassano; Blazej Dolniak; Sonali Joshi; Beata Majchrzak-Kita; Darren P Baker; Nissim Hay; Eleanor N Fish; Leonidas C Platanias
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-13       Impact factor: 11.205

7.  Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation.

Authors:  Kristopher Clark; Lorna Plater; Mark Peggie; Philip Cohen
Journal:  J Biol Chem       Date:  2009-03-22       Impact factor: 5.157

8.  Easy quantification of template-directed CRISPR/Cas9 editing.

Authors:  Eva K Brinkman; Arne N Kousholt; Tim Harmsen; Christ Leemans; Tao Chen; Jos Jonkers; Bas van Steensel
Journal:  Nucleic Acids Res       Date:  2018-06-01       Impact factor: 16.971

9.  Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors.

Authors:  Jianbin Wang; Colin M Exline; Joshua J DeClercq; G Nicholas Llewellyn; Samuel B Hayward; Patrick Wai-Lun Li; David A Shivak; Richard T Surosky; Philip D Gregory; Michael C Holmes; Paula M Cannon
Journal:  Nat Biotechnol       Date:  2015-11-09       Impact factor: 54.908

10.  High-Efficiency Transduction of Primary Human Hematopoietic Stem/Progenitor Cells by AAV6 Vectors: Strategies for Overcoming Donor-Variation and Implications in Genome Editing.

Authors:  Chen Ling; Kanit Bhukhai; Zifei Yin; Mengqun Tan; Mervin C Yoder; Philippe Leboulch; Emmanuel Payen; Arun Srivastava
Journal:  Sci Rep       Date:  2016-10-19       Impact factor: 4.379

View more
  37 in total

1.  Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates.

Authors:  Zulema Romero; Anastasia Lomova; Suzanne Said; Alexandra Miggelbrink; Caroline Y Kuo; Beatriz Campo-Fernandez; Megan D Hoban; Katelyn E Masiuk; Danielle N Clark; Joseph Long; Julie M Sanchez; Miriam Velez; Eric Miyahira; Ruixue Zhang; Devin Brown; Xiaoyan Wang; Yerbol Z Kurmangaliyev; Roger P Hollis; Donald B Kohn
Journal:  Mol Ther       Date:  2019-05-24       Impact factor: 11.454

Review 2.  BAR-Seq clonal tracking of gene-edited cells.

Authors:  Samuele Ferrari; Stefano Beretta; Aurelien Jacob; Davide Cittaro; Luisa Albano; Ivan Merelli; Luigi Naldini; Pietro Genovese
Journal:  Nat Protoc       Date:  2021-05-24       Impact factor: 13.491

Review 3.  Next Generation Precision Medicine: CRISPR-mediated Genome Editing for the Treatment of Neurodegenerative Disorders.

Authors:  Sudhanshu P Raikwar; Nidhi S Kikkeri; Ragha Sakuru; Daniyal Saeed; Haris Zahoor; Keerthivaas Premkumar; Shireen Mentor; Ramasamy Thangavel; Iuliia Dubova; Mohammad Ejaz Ahmed; Govindhasamy P Selvakumar; Duraisamy Kempuraj; Smita Zaheer; Shankar S Iyer; Asgar Zaheer
Journal:  J Neuroimmune Pharmacol       Date:  2019-04-23       Impact factor: 4.147

4.  RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges.

Authors:  Ai-Ming Yu; Young Hee Choi; Mei-Juan Tu
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

Review 5.  The delivery challenge: fulfilling the promise of therapeutic genome editing.

Authors:  Joost van Haasteren; Jie Li; Olivia J Scheideler; Niren Murthy; David V Schaffer
Journal:  Nat Biotechnol       Date:  2020-06-29       Impact factor: 54.908

6.  Enhanced homology-directed repair for highly efficient gene editing in hematopoietic stem/progenitor cells.

Authors:  Suk See De Ravin; Julie Brault; Ronald J Meis; Siyuan Liu; Linhong Li; Mara Pavel-Dinu; Cicera R Lazzarotto; Taylor Liu; Sherry M Koontz; Uimook Choi; Colin L Sweeney; Narda Theobald; GaHyun Lee; Aaron B Clark; Sandra S Burkett; Benjamin P Kleinstiver; Matthew H Porteus; Shengdar Tsai; Douglas B Kuhns; Gary A Dahl; Stephen Headey; Xiaolin Wu; Harry L Malech
Journal:  Blood       Date:  2021-05-13       Impact factor: 22.113

7.  Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem and progenitor cells.

Authors:  M Kyle Cromer; Joab Camarena; Renata M Martin; Benjamin J Lesch; Christopher A Vakulskas; Nicole M Bode; Gavin Kurgan; Michael A Collingwood; Garrett R Rettig; Mark A Behlke; Viktor T Lemgart; Yankai Zhang; Ankush Goyal; Feifei Zhao; Ezequiel Ponce; Waracharee Srifa; Rasmus O Bak; Naoya Uchida; Ravindra Majeti; Vivien A Sheehan; John F Tisdale; Daniel P Dever; Matthew H Porteus
Journal:  Nat Med       Date:  2021-03-18       Impact factor: 53.440

8.  Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development.

Authors:  Paula Cannon; Aravind Asokan; Agnieszka Czechowicz; Paula Hammond; Donald B Kohn; Andre Lieber; Punam Malik; Peter Marks; Matthew Porteus; Els Verhoeyen; Drew Weissman; Irving Weissman; Hans-Peter Kiem
Journal:  Hum Gene Ther       Date:  2021-01       Impact factor: 5.695

9.  High-efficiency CRISPR induction of t(9;11) chromosomal translocations and acute leukemias in human blood stem cells.

Authors:  Johan Jeong; Astraea Jager; Pablo Domizi; Mara Pavel-Dinu; Linda Gojenola; Masayuki Iwasaki; Michael C Wei; Feng Pan; James L Zehnder; Matthew H Porteus; Kara L Davis; Michael L Cleary
Journal:  Blood Adv       Date:  2019-10-08

10.  Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease.

Authors:  Annalisa Lattanzi; Joab Camarena; Premanjali Lahiri; Helen Segal; Waracharee Srifa; Christopher A Vakulskas; Richard L Frock; Josefin Kenrick; Ciaran Lee; Narae Talbott; Jason Skowronski; M Kyle Cromer; Carsten T Charlesworth; Rasmus O Bak; Sruthi Mantri; Gang Bao; David DiGiusto; John Tisdale; J Fraser Wright; Neehar Bhatia; Maria Grazia Roncarolo; Daniel P Dever; Matthew H Porteus
Journal:  Sci Transl Med       Date:  2021-06-16       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.